admin

The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C

Author List
Stephanie Popping
Valeria Cento
Federico García
Francesca Ceccherini-Silberstein
Carole Seguin-Devaux
David van de Vijver
Charles Boucher

Abstract

The World Health Organization (WHO) has declared that hepatitis C virus (HCV) should be eliminated as a public health threat. A key recommendation to reach this elimination goal, is to reduce new infections by 90% and liver-related mortality by 65%. Highly effective direct-acting antiviral agents (DAA) play a major role in this elimination. Unfortunately, DAA treatment fails approximately 2.5–5% of patients, often in the presence of resistance-associated substitutions (RAS). This could eventually lead to a total number of 1.8–3.6 million first-line DAA failures. RAS may jeopardise the elimination goals for several reasons; most importantly, virus transmission and infection progression will continue. More data are required to handle RAS adequately and identify mutational patterns causing resistance. Currently, sample sizes are small, data are scattered and methods heterogenic. Collaboration is therefore key and a European collaboration, such as HEPCARE, should provide a solution.

Article Category

Hepatitis C (HCV)

Article Type

Viewpoints

Posted Date

30-06-2018

Tables & Figures

Back to top